209 related articles for article (PubMed ID: 31491604)
1. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
Lluch A; González-Angulo AM; Casadevall D; Eterovic AK; Martínez de Dueñas E; Zheng X; Guerrero-Zotano Á; Liu S; Pérez R; Chen K; Chacón JI; Mills GB; Antolín S; Blancas I; López-Serra P; Carrasco E; Caballero R; Prat A; Rojo F; Gonzalez-Perez A; Meric-Bernstam F; Albanell J
Eur J Cancer; 2019 Oct; 120():54-64. PubMed ID: 31491604
[TBL] [Abstract][Full Text] [Related]
2. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
4. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
5. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
6. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of androgen receptors in breast cancer subtypes.
Kraby MR; Valla M; Opdahl S; Haugen OA; Sawicka JE; Engstrøm MJ; Bofin AM
Breast Cancer Res Treat; 2018 Nov; 172(2):283-296. PubMed ID: 30109519
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Bernichon E; Vallard A; Wang Q; Attignon V; Pissaloux D; Bachelot T; Heudel PE; Ray-Coquard I; Bonnet E; de la Fouchardière A; Faure C; Chopin N; Beurrier F; Racadot S; Sunyach MP; Rancoule C; Perol D; Corset V; Agrapart V; Tinquaut F; Blay JY; Magné N; Trédan O
Ann Oncol; 2017 Nov; 28(11):2773-2779. PubMed ID: 28945826
[TBL] [Abstract][Full Text] [Related]
12. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
[TBL] [Abstract][Full Text] [Related]
14. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
15. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.
Kutasovic JR; McCart Reed AE; Males R; Sim S; Saunus JM; Dalley A; McEvoy CR; Dedina L; Miller G; Peyton S; Reid L; Lal S; Niland C; Ferguson K; Fellowes AP; Al-Ejeh F; Lakhani SR; Cummings MC; Simpson PT
J Pathol Clin Res; 2019 Jan; 5(1):25-39. PubMed ID: 30246500
[TBL] [Abstract][Full Text] [Related]
16. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
[TBL] [Abstract][Full Text] [Related]
18. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
[TBL] [Abstract][Full Text] [Related]
19. Metastatic progression of breast cancer: insights from 50 years of autopsies.
Cummings MC; Simpson PT; Reid LE; Jayanthan J; Skerman J; Song S; McCart Reed AE; Kutasovic JR; Morey AL; Marquart L; O'Rourke P; Lakhani SR
J Pathol; 2014 Jan; 232(1):23-31. PubMed ID: 24122263
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
